PLX Protalix BioTherapeutics Inc

Price (delayed)

$1.14

Market cap

$83.28M

P/E Ratio

9.5

Dividend/share

N/A

EPS

$0.12

Enterprise value

$85.93M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights

Protalix BioTherapeutics's revenue has increased by 37% YoY and by 2.9% from the previous quarter

PLX's debt is down by 21% YoY

PLX's net income has soared by 156% year-on-year but it is down by 22% since the previous quarter

PLX's EPS has surged by 139% year-on-year but it is down by 14% since the previous quarter

Protalix BioTherapeutics's equity has decreased by 12% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.protalix.com

Peers: FOLD PFE NBIX TEVA

Key stats

What are the main financial stats of PLX

Market

Shares outstanding

73.05M

Market cap

$83.28M

Enterprise value

$85.93M

Valuations

Price to earnings (P/E)

9.5

Price to book (P/B)

2.48

Price to sales (P/S)

1.18

EV/EBIT

8.21

EV/EBITDA

7.38

EV/Sales

1.31

Earnings

Revenue

$65.49M

EBIT

$10.46M

EBITDA

$11.65M

Free cash flow

-$2.47M

Per share

EPS

$0.12

Free cash flow per share

-$0.04

Book value per share

$0.46

Revenue per share

$0.97

TBVPS

$1.25

Balance sheet

Total assets

$84.43M

Total liabilities

$50.87M

Debt

$26.28M

Equity

$33.57M

Working capital

$24.4M

Liquidity

Debt to equity

0.78

Current ratio

1.54

Quick ratio

1.09

Net debt/EBITDA

0.23

Margins

EBITDA margin

17.8%

Gross margin

64.9%

Net margin

12.7%

Operating margin

16%

Efficiency

Return on assets

10.2%

Return on equity

29.7%

Return on invested capital

24.6%

Return on capital employed

26.9%

Return on sales

16%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time

Intraday

-1.72%

1 week

-0.87%

1 month

-8.06%

1 year

-63.81%

YTD

-35.96%

QTD

-9.52%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time

Revenue

$65.49M

Gross profit

$42.51M

Operating income

$10.46M

Net income

$8.31M

Gross margin

64.9%

Net margin

12.7%

Protalix BioTherapeutics's operating income has surged by 180% YoY but it has decreased by 23% QoQ

The operating margin has soared by 159% YoY but it has decreased by 25% from the previous quarter

PLX's net income has soared by 156% year-on-year but it is down by 22% since the previous quarter

PLX's net margin has soared by 141% YoY but it is down by 24% from the previous quarter

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation

P/E

9.5

P/B

2.48

P/S

1.18

EV/EBIT

8.21

EV/EBITDA

7.38

EV/Sales

1.31

PLX's EPS has surged by 139% year-on-year but it is down by 14% since the previous quarter

PLX's P/B is 92% below its last 4 quarters average of 32.5

Protalix BioTherapeutics's equity has decreased by 12% QoQ

PLX's price to sales (P/S) is 45% lower than its last 4 quarters average of 2.2 and 25% lower than its 5-year quarterly average of 1.6

Protalix BioTherapeutics's revenue has increased by 37% YoY and by 2.9% from the previous quarter

Efficiency

How efficient is Protalix BioTherapeutics business performance

The return on invested capital has surged by 187% year-on-year but it has declined by 24% since the previous quarter

PLX's return on sales has surged by 159% year-on-year but it is down by 25% since the previous quarter

The ROA has soared by 141% YoY but it has contracted by 28% from the previous quarter

Protalix BioTherapeutics's return on equity has shrunk by 53% QoQ

Dividends

What is PLX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time

PLX's total assets is 66% greater than its total liabilities

PLX's total assets has surged by 51% year-on-year but it is down by 3.6% since the previous quarter

Protalix BioTherapeutics's quick ratio has increased by 31% YoY but it has decreased by 5% QoQ

PLX's debt is 22% less than its equity

The debt to equity has surged by 125% year-on-year and by 15% since the previous quarter

PLX's debt is down by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.